The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.

Inclusion Criteria:

• Patients diagnosed with ovarian cancer (any histological type) and possessing complete pathological hematoxylin and eosin (HE) stained slides and paraffin-embedded tissue blocks.
• Patients must be 18 years of age or older.
• Patients should not have concurrent multiple primary cancers.
• Patients must undergo an MRI or CT scan prior to starting treatment.
• According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria, patients must have at least one measurable lesion.
• Participants must provide informed consent, voluntarily cooperate with clinical follow-up, and sign an informed consent form.

Exclusion Criteria:

• Patients who do not have accessible tumor tissue required for Homologous Recombination Deficiency (HRD) testing.
• Patients whose clinical records are incomplete, making it impossible to effectively compare treatment efficacy.
• Patients who are lost to follow-up and for whom subsequent treatment outcomes cannot be tracked.